Hospital stocks get capped

Max Healthcare, Apollo Hospitals, Sun Pharma and Dr Reddy’s Laboratories are in focus after the National Pharmaceutical Pricing Authority (NPPA) capped trade margins on 137 anti-cancer drug formulations at 30%, effective November 9, 2026.

The move could reduce maximum retail prices by as much as 70% for certain medicines, although the actual reduction will differ across products. For investors, the key issue is whether the new pricing framework reduces earnings for hospitals, distributors and pharmaceutical companies.

Trigger

• NPPA has capped trade margins on 137 non-scheduled cancer drug formulations at 30%.
• The affected medicines include pembrolizumab, bevacizumab, durvalumab and osimertinib, among others.
• Revised prices become effective November 9, 2026.
• Manufacturers must submit revised prices within seven days of the notification.
• Hospitals and pharmacies must charge the revised prices and publicly display them.
• The measure builds on a similar 2019 intervention covering 42 anti-cancer drugs.

The immediate impact is likely to be more visible for hospital chains such as Max Healthcare and Apollo Hospitals, which procure cancer medicines and dispense them through hospital pharmacies. If their existing mark-ups exceed the new limit, revenue and margins from these medicines could come under pressure. However, cheaper treatment may eventually improve affordability and patient volumes, partly offsetting the impact. Fortis Healthcare and Global Health (Medanta) are other listed hospital operators worth watching.

For Sun Pharma and Dr Reddy’s, the impact is less straightforward. The regulation primarily targets excessive margins between the manufacturer and the patient, rather than imposing a uniform 70% cut on pharmaceutical manufacturers' selling prices. The government has explicitly stated that the framework aims to protect legitimate manufacturer revenues. Actual exposure will depend on the companies' affected products and distribution arrangements.

The scale of the intervention is significant. Regulatory discussions identified average trade mark-ups of around 170% on non-scheduled cancer medicines, with some reaching 700%. The revised framework is expected to generate annual patient savings of approximately Rs. 2,500 crore. This could change the economics of cancer treatment, particularly for high-value immunotherapy medicines.

The caution is that a 70% reduction in a medicine's MRP does not mean a 70% reduction in a hospital's or pharmaceutical company's earnings. For hospitals, the principal risk is lost pharmacy margins; for drug manufacturers, it is the extent of product-level exposure and any changes in pricing arrangements. The market will now watch the revised price lists, company disclosures and management commentary to assess the actual earnings impact.

The market takeaway: The move is structurally positive for patients, potentially negative for hospital pharmacy margins, but its impact on listed pharmaceutical manufacturers is likely to be company- and product-specific rather than uniform.